title: AT1 receptor mRNA antisense normalizes enhanced cardiac sympathetic afferent reflex in rats with chronic heart failure.
abstract: Previous studies showed that the cardiac sympathetic afferent reflex (CSAR) is enhanced in dogs and rats with chronic heart failure (CHF) and that central ANG II type 1 receptors (AT(1)R) are involved in this augmented reflex. The aim of this study was to determine whether intracerebroventricular administration and microinjection of antisense oligodeoxynucleotides targeted to AT(1)R mRNA would attenuate the enhanced CSAR and decrease resting renal sympathetic nerve activity (RSNA) in rats with coronary ligation-induced CHF. The CSAR was elicited by application of bradykinin to the epicardial surface of the left ventricle. Reflex responses to epicardial administration of bradykinin were enhanced in rats with CHF. The response to bradykinin was determined every 50 min after intracerebroventricular administration (lateral ventricle) or microinjection (into paraventricular nucleus) of antisense or scrambled oligonucleotides to AT(1)R mRNA. AT(1)R mRNA and protein levels in the paraventricular nucleus were significantly reduced 5 h after administration of antisense. Antisense significantly decreased resting RSNA and normalized the enhanced CSAR responses to bradykinin in rats with CHF. Scrambled oligonucleotides did not alter resting RSNA or the enhanced responses to bradykinin in rats with CHF. No significant effects were found in sham-operated rats after administration of either antisense or scrambled oligonucleotides. These results strongly suggest that central AT(1)R mRNA antisense reduces expression of AT(1)R protein and normalizes the augmentation of this excitatory sympathetic reflex and that genetic manipulation of protein expression can be used to normalize the sympathetic enhancement in CHF.
authors.affiliation: Dept. of Cellular and Integrative Physiology, University of Nebraska College of Medicine, 985850 Nebraska Medical Center, Omaha, NE 68198-5850, USA.
authors.forename: Guo-Qing
authors.initials: GQ
authors.lastname: Zhu
authors.forename: Lie
authors.initials: L
authors.lastname: Gao
authors.forename: Yifan
authors.initials: Y
authors.lastname: Li
authors.forename: Kaushik P
authors.initials: KP
authors.lastname: Patel
authors.forename: Irving H
authors.initials: IH
authors.lastname: Zucker
authors.forename: Wei
authors.initials: W
authors.lastname: Wang
mesh_terms: D000818:Animals; D001794:Blood Pressure; D002908:Chronic Disease; D015316:Genetic Therapy / Q000379:methods*; D006321:Heart / Q000294:innervation*; D006333:Heart Failure / Q000503:physiopathology* / Q000628:therapy*; D006339:Heart Rate; D007276:Injections, Intraventricular; D007668:Kidney / Q000294:innervation; D008297:Male; D020319:Oligodeoxyribonucleotides, Antisense / Q000494:pharmacology; D010286:Paraventricular Hypothalamic Nucleus / Q000502:physiology; D012333:RNA, Messenger; D051381:Rats; D017207:Rats, Sprague-Dawley; D044140:Receptor, Angiotensin, Type 1 / Q000235:genetics*; D013318:Stroke Volume; D013564:Sympathetic Nervous System / Q000503:physiopathology*
chemical_list: D020319:Oligodeoxyribonucleotides, Antisense; D012333:RNA, Messenger; D044140:Receptor, Angiotensin, Type 1